PLA2R Antagonist Binding for Membranous Nephropathy Autoantibodies

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for membranous nephropathy, particularly primary membranous nephropathy, are not therapeutic for all patients and may produce negative side effects, with a high titer group often being unresponsive to low dosage rituximab, highlighting the need for novel treatment strategies.

Innovation Solution

Development of an anti-phospholipase A2 receptor (PLA2R) antibody or recombinant protein antagonist that binds to the C-type lectin-like domain 1 (CTLD1) domain or cysteine-rich (CysR) domain of a phospholipase A2 receptor (PLA2R) to block the binding of anti-PLA2R autoantibodies and PLA2R, thereby inhibiting complement-dependent cytotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional immunosuppressive therapy (e.g., rituximab, cyclophosphamide combined with steroids) is used to treat membranous nephropathy, then some patients can be treated, but the treatment is not effective for all patients and produces negative side effects

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidnegative side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a soluble PLA2R1 protein as an intermediary that binds to anti-PLA2R autoantibodies, preventing them from binding to podocyte PLA2R. This intermediary approach neutralizes the harmful autoimmune response without requiring broad immunosuppression, thereby reducing side effects while maintaining treatment effectiveness.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful effect of high levels of anti-PLA2R autoantibodies into a beneficial diagnostic and therapeutic target. By measuring anti-PLA2R antibody levels and using soluble PLA2R1 to neutralize them, the treatment specifically addresses the pathogenic mechanism while avoiding non-specific immunosuppression and its associated side effects.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Object-affected harmful factors

If low dosage rituximab is used to treat membranous nephropathy, then treatment cost and side effects are reduced, but high titer patients are unresponsive to treatment

Engineering Contradiction:

Improveside effectsVSAvoidtreatment responsiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the therapeutic parameter from immunosuppressive agents (rituximab, cyclophosphamide) to a specific antigen-binding approach using soluble PLA2R1. This parameter change allows for effective treatment of high titer patients without the dose-limiting side effects of conventional immunosuppressants, as the soluble protein directly neutralizes autoantibodies regardless of their concentration.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If current immunosuppressive treatments are used, then some therapeutic effect can be achieved, but they do not address the specific pathogenic mechanism of anti-PLA2R autoantibodies

Engineering Contradiction:

Improvetherapeutic effectVSAvoidmechanism-specific targeting

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by targeting the specific pathogenic mechanism of anti-PLA2R autoantibodies binding to podocyte PLA2R. The soluble PLA2R1 protein is designed with the specific binding properties needed to neutralize these autoantibodies, providing mechanism-specific therapy rather than broad immunosuppression, thereby improving both effectiveness and adaptability.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antagonist effectively blocks the binding of anti-PLA2R autoantibodies to reduce cell damage by blocking the binding of the anti-PLA2R autoantibodies, thereby reducing cell damage and complement-dependent cytotoxicity, providing a novel therapeutic approach for membranous nephropathy.

Implementation Method 1

an anti-phospholipase A2 receptor (PLA2R) antibody... which is configured to bind to a C-type lectin-like domain 1 (CTLD1) domain or a cysteine-rich (CysR) domain of a phospholipase A2 receptor (PLA2R)

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

inhibiting complement-dependent cytotoxicity

Methodology Applied

Scientific EffectComplement-dependent cytotoxicity:

Data Source

PatentEP4660204A1Antagonist for use in treatment of membranous nephropathy

Publication Date: 2025.12.10 CHANG GUNG UNIVERSITY

Figure 1~2
Figure 3
Figure 4~5

AI summary

An antagonist for treating membranous nephropathy and use of the antagonist in the manufacture of a pharmaceutical composition for treating the membranous nephropathy. The antagonist is an antibody that is configured to bind to a C-type lectin-like domain 1 (CTLD1) domain or a cysteine-rich (CysR) domain of a phospholipase A2 receptor (PLA2R), or is a recombinant protein that binds to an anti-PLA2R autoantibody.